---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-094174"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2026-08-27T13:05:14+00:00"
generated_at: "2026-08-27T13:06:03.462983+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroOne reports successful large-animal StereoCED procedures; human studies planned this quarter

## Summary
- Three large-animal procedures completed using next-gen StereoCED platform at University of Minnesota.
- In two procedures, drug delivery electrodes delivered study agent and recorded intracranial electrophysiological activity from same regions.
- Robotic platform used for trajectory, drilling, and anchor bolt placement; drug delivery and recording successful.
- StereoCED revenue expected in fiscal Q4 2026; human investigational device release planned by end of Q4 2026.
- CEO Dave Rosa cites repeatability and progress toward human investigational clinical studies later this quarter.

## SEC filing metadata
- accession: 0001213900-26-094174
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2026-08-27T13:05:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390026094174/0001213900-26-094174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390026094174/ea0303530-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-094174
- JSON: https://secwatch.observer/filing/0001213900-26-094174.json
- Plain text: https://secwatch.observer/filing/0001213900-26-094174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.